Education
About Us
Working with TipRanks
Follow Us
Rhythm Biosciences Ltd. (AU:RHY)
ASX:RHY
RHY Stock Chart & Stats
AU$0.14
<AU$0.01(1.16%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(1.16%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.28
Previous CloseN/A
Volume786.78K
Average Volume (3M)462.98K
Market Cap
AU$69.21M
Enterprise ValueAU$72.22M
Total Cash (Recent Filing)AU$1.73M
Total Debt (Recent Filing)AU$262.44K
Price to Earnings (P/E)―
Beta0.89
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding337,605,470
10 Day Avg. Volume510,821
30 Day Avg. Volume462,976
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)22.03
Price to Sales (P/S)4.56
P/FCF Ratio-4.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Diagnostic Product PipelineRhythm’s business model centers on Colostat, a targeted blood-based colorectal cancer screening test. A single, clinically focused product with a clear population-screening use case supports scalable commercialization, recurring testing demand, and focused R&D spend, aligning incentives for durable adoption over multiple years.
High Gross Profit MarginReported high gross margins imply attractive unit economics for the test itself; once fixed costs are absorbed by higher volumes, gross-margin leverage can drive meaningful improvement in operating profitability. This structural margin advantage helps long-term viability if commercial uptake scales.
Improving Free Cash Flow TrendsThe move toward improved free cash flow, even from negative operating cash flow, signals operational progress in cash management and capital allocation. If sustained, this trend can extend runway, reduce dependency on dilutive financing and support gradual commercialization investments over months to years.
Bears Say
Sharp Revenue DeclineA steep ~43% revenue drop reflects weak commercial traction or one-off setbacks and raises concern about product adoption and revenue stability. Over the medium term, declining topline undermines the ability to scale fixed-cost-intensive diagnostics and delays achievement of break-even economics.
Persistent UnprofitabilitySustained negative EBIT and EBITDA margins indicate ongoing operating inefficiencies and inability to cover fixed costs from core operations. This structural unprofitability forces reliance on external capital, limits reinvestment capacity, and heightens execution risk across commercialization and regulatory pathways.
Elevated LeverageA debt-to-equity ratio around 1.7 creates meaningful financial leverage risk for a pre-profit diagnostics firm. Interest and principal obligations reduce operational flexibility, limit ability to fund commercialization, and increase vulnerability to adverse revenue or reimbursement outcomes over the medium term.
Rhythm Biosciences Ltd. News
RHY FAQ
What was Rhythm Biosciences Ltd.’s price range in the past 12 months?
Rhythm Biosciences Ltd. lowest share price was AU$0.05 and its highest was AU$0.28 in the past 12 months.
What is Rhythm Biosciences Ltd.’s market cap?
Rhythm Biosciences Ltd.’s market cap is AU$69.21M.
When is Rhythm Biosciences Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rhythm Biosciences Ltd.’s earnings last quarter?
Currently, no data Available
Is Rhythm Biosciences Ltd. overvalued?
According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued.
Does Rhythm Biosciences Ltd. pay dividends?
Rhythm Biosciences Ltd. does not currently pay dividends.
What is Rhythm Biosciences Ltd.’s EPS estimate?
Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rhythm Biosciences Ltd. have?
Rhythm Biosciences Ltd. has 337,605,470 shares outstanding.
What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?
Currently, no hedge funds are holding shares in AU:RHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Biosciences Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RHY Sentiment 66%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$34.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.00%
12-Months-Change
Fundamentals
Return on Equity
-501.54%
Trailing 12-Months
Asset Growth
86.46%
Trailing 12-Months
Company Description
Rhythm Biosciences Ltd.
Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―